Estados financieros detallados de Entrada Therapeutics, Inc. (TRDA): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto -7.5%, margen operativo -37.7%, margen neto -35.4%.
Al precio actual de $6.89, TRDA presenta beneficios negativos (P/E no significativo) y un ROE del -57.61%. La capitalización bursátil es de $267M.
Cuenta de Resultados (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Ingresos | 0 | 0 | 0 | 0 | $129.0M | $210.8M | $25.4M |
| Coste de Ventas | $104000 | $326000 | 0 | 0 | 0 | 0 | $4.1M |
| Beneficio Bruto | -$104000 | -$326000 | 0 | 0 | $129.0M | $210.8M | $21.3M |
| I+D | $8.2M | $21.1M | $35.9M | $66.6M | $99.9M | $125.3M | $142.3M |
| Generales y Administrativos | $3.6M | $5.2M | $15.2M | $30.6M | $32.3M | $38.5M | $41.0M |
| Gastos Operativos | $11.8M | $26.3M | $51.1M | $97.2M | $132.2M | $163.8M | $177.3M |
| Beneficio Operativo | -$11.8M | -$26.7M | -$51.1M | -$97.2M | -$3.2M | $47.0M | -$156.0M |
| EBITDA | -$11.7M | -$26.2M | -$50.0M | -$90.1M | $14.9M | $70.3M | -$142.4M |
| Gastos por Intereses | 0 | 0 | 0 | $2.6M | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$5.1M | -$26.5M | -$51.2M | -$94.6M | $12.1M | $66.5M | -$142.8M |
| Impuestos | 0 | 0 | 0 | 0 | $18.7M | $859000 | $924000 |
| Beneficio Neto | -$4.6M | -$26.5M | -$51.2M | -$94.6M | -$6.7M | $65.6M | -$143.8M |
| BPA | $-4.44 | $-0.84 | $-1.60 | $-2.79 | $-0.20 | $1.76 | $-3.47 |
| BPA Diluido | $-4.44 | $-0.84 | $-1.60 | $-2.79 | $-0.20 | $1.68 | $-3.47 |
| Acciones en Circulación (Diluidas) | $1.0M | $31.2M | $31.2M | $31.3M | $33.1M | $39.0M | $41.4M |
Balance (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Caja y Equivalentes | $16.8M | $39.0M | $291.1M | $45.2M | $67.6M | $101.2M | $90.4M |
| Inversiones a Corto | 0 | 0 | 0 | $143.6M | $284.4M | $318.8M | $205.3M |
| Cuentas por Cobrar | 0 | 0 | 0 | 0 | $5.9M | $3.7M | $2.6M |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $17.4M | $39.9M | $298.7M | $209.9M | $369.8M | $440.0M | $306.3M |
| Inmovilizado Material | $801000 | $3.0M | $6.3M | $33.0M | $92.7M | $82.0M | $67.8M |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $18.2M | $43.5M | $305.8M | $252.1M | $469.2M | $526.3M | $377.4M |
| Cuentas por Pagar | $710000 | $1.6M | $706000 | $6.0M | $3.3M | $4.3M | $2.3M |
| Deuda a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Corrientes | $1.9M | $3.4M | $6.7M | $22.0M | $158.8M | $39.5M | $24.5M |
| Deuda a Largo | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Totales | $33.8M | $85.0M | $7.1M | $39.5M | $226.8M | $97.6M | $71.2M |
| Reservas | -$16.0M | -$42.5M | -$93.7M | -$188.3M | -$195.0M | -$129.3M | -$273.1M |
| Patrimonio Neto | -$15.5M | -$41.5M | $298.7M | $212.6M | $242.4M | $428.7M | $306.1M |
| Deuda Total | 0 | 0 | 0 | $25.9M | $68.2M | $59.2M | $50.9M |
| Deuda Neta | -$16.8M | -$39.0M | -$291.1M | -$162.8M | -$283.7M | -$360.8M | -$244.8M |
| Capital Circulante | $15.5M | $36.6M | $292.0M | $187.9M | $211.0M | $400.6M | $281.8M |
Flujo de Caja (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Beneficio Neto | -$5.1M | -$26.5M | -$51.2M | -$94.6M | -$6.7M | $65.6M | -$143.8M |
| Amortizaciones | $104000 | $326000 | $1.1M | $1.9M | $2.8M | $3.8M | $4.1M |
| Compensación en Acciones | $294000 | $325000 | $2.5M | $9.9M | $13.1M | $17.9M | $19.6M |
| Cambio en Capital Circulante | $174000 | $282000 | -$3.4M | -$11.1M | $136.3M | -$118.9M | -$4.8M |
| Flujo de Caja Operativo | -$10.8M | -$25.6M | -$50.9M | -$93.8M | $139.8M | -$41.6M | -$128.5M |
| Inversiones (CapEx) | -$630000 | -$2.3M | -$4.6M | -$2.9M | -$5.6M | -$3.2M | -$1.0M |
| Adquisiciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$11.4M | -$27.9M | -$55.4M | -$96.7M | $134.2M | -$44.7M | -$129.6M |
Crecimiento y Márgenes (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Crecimiento Ingresos (anual) | +63.4% | -87.9% | |||||
| Crecimiento Beneficio Neto (anual) | -470.5% | -92.9% | -84.9% | +92.9% | +1081.7% | -319.0% | |
| Crecimiento BPA (anual) | +81.1% | -90.5% | -74.4% | +92.8% | +980.0% | -297.2% | |
| Cambio en Acciones (anual) | +2881.7% | -0.1% | +0.2% | +5.6% | +18.0% | +6.1% | |
| Crecimiento FCF (anual) | -144.0% | -98.8% | -74.4% | +238.8% | -133.3% | -189.7% | |
| Margen Bruto | 100.0% | 100.0% | 83.9% | ||||
| Margen Operativo | -2.5% | 22.3% | -613.7% | ||||
| Margen EBITDA | 11.5% | 33.3% | -560.2% | ||||
| Margen Neto | -5.2% | 31.1% | -565.5% | ||||
| Margen FCF | 104.0% | -21.2% | -509.6% | ||||
| Tasa Impositiva Efectiva | -0.0% | -0.0% | -0.0% | -0.0% | 155.4% | 1.3% | -0.6% |
Datos por Acción (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| FCF por Acción | $-10.91 | $-0.89 | $-1.78 | $-3.09 | $4.06 | $-1.15 | $-3.13 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $1.0M | $31.2M | $31.2M | $31.3M | $33.1M | $37.3M | $41.4M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -57.61% |
| Rentabilidad sobre capital invertido | -62.61% |
| Rentabilidad sobre activos | -55.47% |
| Margen bruto | -754.72% |
| Margen operativo | -3767.07% |
| Margen neto | -3537.73% |
Salud financiera
| Deuda / Patrimonio | 0.21 |
| Ratio corriente | 10.89 |
| Piotroski F-Score | 2 |
| Altman Z-Score | 2.17 |
Ratios Clave (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| P/E | -5.39 | -28.51 | -10.70 | -4.85 | -75.45 | 9.82 | -2.96 |
| P/VC | -1.62 | -18.04 | 1.79 | 1.99 | 2.06 | 1.50 | 1.39 |
| P/V | 0.00 | 0.00 | 0.00 | 0.00 | 3.87 | 3.06 | 16.73 |
| Margen Bruto | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% | 100.0% | 83.9% |
| Margen Operativo | 0.0% | 0.0% | 0.0% | 0.0% | -2.5% | 22.3% | -613.7% |
| Margen Neto | 0.0% | 0.0% | 0.0% | 0.0% | -5.2% | 31.1% | -565.5% |
Empresas relacionadas: ACHV · ALLO · ARCT · AVIR · CAPR · HUMA · IMRX
Explorar sector: Healthcare · Biotechnology
Más secciones de TRDA: Resumen · Valoración · Estadísticas · Estimaciones · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones